Skip to main content

Table 2 Characteristics of fully published trials according to whether the study identifier is present

From: Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

  Presence or absence of study identifier in the published article
Yes (n = 71) No (n = 18)
Study phase, n (%)
 Phase 1 17 (24) 12 (67)
 Phase 2 38 (54) 6 (33)
 Phase 3 16 (23) 0
Drug type, n (%)
 Immune checkpoint inhibitors 18 (25) 1 (6)
 Other anticancer drugs 53 (75) 17 (94)
 Sample size, median (interquartile range) 102 (53–345) 42 (37–56)
 Multi-country study, n (%) 46 (65) 5 (28)
 Author affiliation with industry, n (%) 71 (100) 16 (89)
 Statistically significant outcomeª, n (%) 17 (24) 0
 Reporting of adverse events, n (%) 71 (100) 18 (100)
 Selective outcome reporting, n (%) 8 (11) 7 (39)
  1. ªAt least 1 of the primary outcomes was statistically significant
\